Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Avid Nano
San Diego, California, USA
- Ownership
- Private
- Development stage
- Other
01
Overview
Avidity has demonstrated the first-ever successful targeted delivery of RNA into muscle tissue. The lead program, AOC 1001 (delpacibart etedesiran/del-desiran), is in Phase 3 HARBOR trial for DM1. Clinical programs across three rare muscle diseases show consistent data.
- Therapeutic areas
- CardiovascularImmunologyNeurologyRare Diseases
- Modalities
- Antibody oligonucleotide conjugates (AOCs)Antisense oligonucleotideRNA therapy
- Industry
- Biotech
02
Partnerships
Bristol Myers Squibb (ongoing collaboration)Eli Lilly (2019 partnership)
Beyond the preview
Go deeper on Avid Nano.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Avid Nano.